Wednesday, August 5, 2015

Top 5 Construction Material Stocks To Buy For 2016

Top 5 Construction Material Stocks To Buy For 2016: CEMEX SAB de CV (CX)

CEMEX, S.A.B. de C.V. (CEMEX), incorporated on January 20, 1931, is a global cement manufacturer with operations in North America, Europe, South America, Central America, the Caribbean, Africa, the Middle East and Asia. The Company is a holding company engaged through the operating subsidiaries in the production, distribution, marketing and sale of cement, ready-mix concrete, aggregates and clinker. As of December 31, 2009, the Company's cement production facilities were located in Mexico, the United States, Spain, the United Kingdom, Germany, Poland, Croatia, Latvia, Colombia, Costa Rica, the Dominican Republic, Panama, Nicaragua, Puerto Rico, Egypt, the Philippines and Thailand.

The Company manufactures cement through a closely controlled chemical process, which begins with the mining and crushing of limestone and clay, and, in some instances, other raw materials. The clay and limestone are then pre-homogenized, a process which consists of combining diffe rent types of clay and limestone. The mix is typically dried, then fed into a grinder, which grinds the various materials in preparation for the kiln. The raw materials are calcined, or processed, at a very high temperature in a kiln, to produce clinker. Clinker is the intermediate product used in the manufacture of cement.

Ready-mix concrete is a combination of cement, fine and coarse aggregates, admixtures (which control properties of the concrete including plasticity, pumpability, freeze-thaw resistance, strength and setting time), and water. The Company is a supplier of aggregates primarily the crushed stone, sand and gravel, used in virtually all forms of construction.

Mexican Operations

During the year ended December 31, 2009, the Mexican operations represented approximately 21% of the Company's net sales! . CEMEX Mexico is a direct subsidiary of CEMEX and is both a holding company for some of the operating companies in Mexico a nd an operating company involved in the manufacturing and ma! rketing of cement, plaster, gypsum, groundstone and other construction materials and cement by-products in Mexico. CEMEX Mexico, indirectly, is also the holding company for the international operations. The Company owns Tolteca, Monterrey, Maya, Anahuac, Campana, Gallo, and Centenario brands in Mexico. As of December 31, 2009, the Company owned 100% of CEMEX Mexico.

The Company competes with Holcim Ltd., Sociedad Cooperativa Cruz Azul, Cementos Moctezuma, Grupo Cementos Chihuahua and Lafarge Cementos in Mexico.

U.S. Operations

As of December 31, 2009, the Company's operations in the United States represented approximately 19% of the Company's net sales. As of December 31, 2009, the Company held 100% of CEMEX, Inc. As of December 31, 2009, CEMEX had a cement manufacturing capacity of approximately 17.9 million tons per year in the United States operations. As of December 31, 2009, the Company operated 14 cement plants located in Al abama, California, Colorado, Florida, Georgia, Kentucky, Ohio, Pennsylvania, Tennessee and Texas. As of December 31, 2009, it also had 48 rails or water served active cement distribution terminals in the United States. As of December 31, 2009, the Company had 336 ready-mix concrete plants located in the Carolinas, Florida, Georgia, Texas, New Mexico, Nevada, Arizona, California, Oregon and Washington and aggregates facilities in North Carolina, South Carolina, Arizona, California, Florida, Georgia, Kentucky, New Mexico, Nevada, Oregon, Texas, and Washington.

Spanish Operations

As of December 31, 2009, the operations in Spain represented approximately 5% of the Company's net sales. As of December 31, 2009, the Company held approximately 99.8% of CEMEX Espana, the main operating subsidiary in Spain. The cement activitie! s in Spai! n are conducted by CEMEX Espana. The ready-mix concrete activities in Spain are conducted by Hormicemex, S.A., a subsidiar y of CEMEX Espana, and the aggregates activities in Spain ar! e conduct! ed by Aricemex S.A., also a subsidiary of CEMEX Espana.

U.K. Operations

As of December 31, 2009, the Company's operations in the United Kingdom represented approximately 8% of the Company's net sales. As of December 31, 2009, it held 100% of CEMEX Investments Limited, the holding subsidiary in the United Kingdom. The Company is a provider of building materials in the United Kingdom with vertically integrated cement, ready-mix concrete, aggregates and asphalt operations. It is also a provider of concrete and precast materials solutions, such as concrete blocks, concrete block paving, roof tiles, flooring systems and sleepers for rail infrastructure.

The Company competes with Lafarge, Heidelberg, Tarmac, and Aggregate Industries in the United Kingdom.

German Operations

As of December 31, 2009, the operations in the Rest of Europe consisted of the operations in Germany, France, Ireland, Poland, Croatia, the Czech Republic, Latvia, Austria and Hungary, as well as the other European assets. The Company is a provider of building materials in Germany, with vertically integrated cement, ready-mix concrete, aggregates and concrete products operations (consisting mainly of prefabricated concrete ceilings and walls). It maintains a network for ready-mix concrete and aggregates in Germany. As of December 31, 2009, the Company held 100% of CEMEX Deutschland AG, the holding subsidiary in Germany.

The Company competes with Heidelberg, Dyckerhoff, Lafarge, Holcim and Schwenk in Germany.

French Operations

As of December 31, 2009, the Company held 100% of CEMEX France Gestion (S.A.S.), the holding subsidiary in France. It is a ready-mix concrete producer and aggregate producer in France. As of December 31, 2009, ! the Compa! ny operated 239 ready-mix concrete plants in France, one maritime cement terminal located in LeHavre, on the northern coast of Franc e, 20 land distribution centers and 42 aggregates quarries.

The Company competes with Lafarge, Holcim, Italcementi, Vicat, Lafarge, Italcementi, Colas (Bouygues) and Eurovia (Vinci) in France.

Irish Operations

As of December 31, 2009, the Company held approximately 61.2% of Readymix Plc, the operating subsidiary in the Republic of Ireland. The operations in Ireland produce and supply sand, stone and gravel, as well as ready-mix concrete, mortar and concrete blocks. As of December 31, 2009, we operated 43 ready-mix concrete plants, 27 aggregates quarries and 15 block plants located in the Republic of Ireland, Northern Ireland and the Isle of Man. The Company imports and distributes cement in the Isle of Man.

The Company competes with CRH, the Lagan Group and Kilsaran in the Republic of Ireland.

Polish Operations

As of December 31, 2009, the Company held 100% of CEMEX Polska Sp. z.o.o. (CEMEX Polska), the holding subsidiary in Poland. It is a provider of building mat erials in Poland serving the cement, ready-mix concrete and aggregates markets. As of December 31, 2009, CEMEX operated two cement plants and one grinding mill in Poland, with a total installed cement capacity of three million tons per year. As of December 31, 2009, the Company also operated 39 ready-mix concrete plants and nine aggregates quarries in Poland. As of December 31, 2009, the Company also operated 10 land distribution centers and two maritime terminals in Poland.

The Company competes with Heidelberg, Lafarge, CRH and Dyckerhoff in Poland.

Southeast European Operations

As of December 31, 2009, the Company held 100% of CEMEX Hrvatska d.d. (Hrvatska), the operating subsidiary in Croatia. As of December 31, 2009, it operated three cement plants in Croatia, with an installed capac! ity of 2.! 4 million tons per year. As of December 31, 2009, the Company also operated ten land distribution centers, three maritime cement terminals, e ight ready-mix concrete facilities and one aggregates quarry! in Croat! ia, Bosnia and Herzegovina, Slovenia, Serbia and Montenegro.

Advisors' Opinion:
  • [By GuruFocus]

    George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares,! 2.1% of ! the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.2 7, with an estimated

  • [By Monica Wolfe]

    Cemex SAB de CV (CX)

    As of the close of the third quarter there were nine guru owners of Cemex. These gurus held a combined weighting of 5.30%. During the third quarter, there were three gurus making buys and nine making sells of their stake in CX.

  • [By Ben Levisohn]

    Shares of Vulcan have gained 7.6%, and given a lift to other cement makers today, including Martin Marietta Materials (MLM), which has risen 4.9% and reports earnings on Thursday, Cemex (CX), which has advanced 1.5%, and Texas Industries (TXI), which is up 4.9%.

  • [By Dan Caplinger]

    Even now, though, it's far from clear whether the recent rebound has staying power. Earlier this month, peer Vulcan Materials (NYSE: VMC  ) reported 5% lower shipments of aggregates, although rising prices helped offset the impact, and the company noted double-digit-percentage increases in shipments to hot housing areas including Arizona, California, and Florida. Similarly, Cemex (NYSE: CX  ) posted a substantial loss for its March quarter on with 5% lower revenue, but the Mexican company pointed to strength in the U.S. and Asian markets as offsetting weakness in Mexico, Europe, and Latin America.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-construction-material-stocks-to-buy-for-2016-2.html

Sunday, August 2, 2015

Top Clean Energy Stocks To Buy For 2016

Top Clean Energy Stocks To Buy For 2016: Coronado Biosciences Inc (CNDO)

Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company's two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn's disease (Crohn's), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.

TSO

TSO is the microscopic eggs of a parasitic helminth, or worm, that is found in pigs. In September 2011, the Company filed an Investigational New Drug Application (IND) with t he United States Food and Drug Administration (FDA) and it initiated a single dose, dose escalation study in patients with Crohn's in February 2012. The Phase 1 clinical trial was a multi-center, sequential dose-escalation, double-blind, placebo-controlled study, the primary objective of which was to evaluate the safety and tolerability of TSO. The trial enrolled 36 patients with Crohn's ranging in age from 20 to 54 with an equal distribution of male and female patients in three single dose cohorts of orally administered 500, 2500 and 7500 ova. Each cohort had 12 patients, with nine patients receiving TSO and three receiving placebo.

CNDO-109

CNDO-109 is a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor NK cells. CTV-1 is a leukemic cell line recently re-class! ified as a T-cell acute lymphocytic leukemia (ALL). The Company has worldwide rights to develop and commercialize CNDO-109 activated NK cells for the treatment of cancer fro! m UCLB. In February 2012, the Company submitted an IND for the CNDO-109 activated NK cell product in the United States. The treatment of patients with CNDO-109 activated NK cells involves several steps. The activated NK cells are infused into the patient after resting NK cells are incubated with CNDO-109 for at least eight hours. Preparation of CNDO-109 activated NK cells takes about 24 hours from start to finish.

The Company competes with Centocor Ortho Biotech Inc.'s Remicade , UCB S.A.'s Cimzia, Abbott Laboratories' Humira, Biogen Idec's Avonex, Bayer Healthcare Pharmaceuticals' Betaseron, Teva Pharmaceuticals Industries, Ltd.'s Copaxone and Novartis AG's Gilenya.

Advisors' Opinion:
  • [By Roberto Pedone]

    One under-$10 biopharmaceutical player that's quickly moving within range of triggering a major breakout trade is Coronado Biosciences (CNDO), which is focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. This stock has been hit hard by the bears in 2013, with shares off by 43%.

    If you take a look at the chart for Coronado Biosciences, you'll notice that this stock has been uptrending strong since it double bottomed in November, with shares moving higher from its low of $1.25 to its intraday high of $2.58 a share. During that uptrend, shares of CNDO have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CNDO within range of triggering a major breakout trade.

    Traders should now look for long-biased trades in CNDO if it manages to break out above some key overhead resistance at $2.70 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.97 million shares.! If that ! breakout hits soon, then CNDO will set up to re-fill some of its previous gap down zone from October that started near $7 a share. Some possible upside targets if CNDO gets into that gap with volume are $4 to $5 a share.

    Traders can look to buy CNDO off any weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support at $2 a share. One can also buy CNDO off strength once it takes out $2.70 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By Ben Fox Rubin]

    Biopharmaceutical firm Coronado Biosciences Inc.(CNDO) said a recent pilot study found that the first five patients using its potential autism treatment showed statistically significant separation from placebo, in favor of the drug. The treatment was also well-tolerated. The study is still ongoing. Shares jumped 26% to $2.25 premarket.

  • [By James E. Brumley]

    The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that pl agued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.

    s! ource from Top Stocks For 2015:http://www.topstocksblog.com/top-clean-energy-stocks-to-buy-for-2016-2.html